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“oral antiviral treatment” on the other side are consid-
ered. Ultimately the authors evaluated the eﬃcacy of ten-
ofovir vs. all other drugs as the diﬀerences between
response rates obtained from diﬀerent trials. However
when diﬀerent treatments are studied in separate trials
actual diﬀerences between response rates associated with
the treatments (treatment eﬀect) are confounded by the
diﬀerences between the trials (trial eﬀect), thus it is
impossible to estimate the eﬀects separately. Typically,
trial eﬀects are due to diﬀerent patients characteristics
(e.g. baseline, viral load). With regard to the cost of ther-
apy used in the model it seems that only the cost of drugs
was considered without considering the additional cost
due to the administration cost, toxicity (e.g. monitoring
of renal function for tenofovir) management of side-ef-
fects etc. Consequently, the model does not seem sensi-
tive and precise enough for the purpose of comparing
active treatments one against the other (see Table 1).
True and appropriate incremental cost per QALY
(Quality Adjusted Life Year) gained of each individual
oral antiviral therapy compared to “no treatment” can
be computed, which are based on the very data of Buti
and colleagues [1].
Once this standard approach for computing ICER is
used, one can observe that all oral antiviral therapies are
cost-eﬀective compared to “no treatment”, far below the
commonly agreed threshold of 50.000 Euro per QALY.
This is reassuring for the decision makers that oral anti-
viral therapies are value for money, so that the decision
on appropriate therapy for the next patient can safely re-
turn in the sphere of clinical judgment and physician–
patient interaction.
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Table 1
ICER of each active treatment vs. no treatment.
Cost QALY Incremental cost Incremental QALY ICERa
HBeAg positive pts
No treatment 83,406 13.69 Reference Reference
Telbivudine 90,721 14.96 7315 1.27 5760
Entecavir 90,273 15.21 6867 1.52 4518
Adefovir 91,199 14.68 7793 0.99 7872
Lamivudine 87,134 14.67 3728 0.98 3804
Tenofovir 87,615 15.43 4209 1.74 2419
HBeAg negative pts
No treatment 90,866 12.48 Reference Reference
Telbivudine 111,097 15.47 20,231 2.99 6766
Entecavir 114,968 16.11 24,102 3.63 6640
Adefovir 103,916 14.21 13,050 1.73 7543
Lamivudine 95,547 14.30 4681 1.82 2572
Tenofovir 105,889 16.28 15,023 3.8 3953
Bold value represents the higher and lowest value in the group.
Abbreviations: RCT, Randomized Clinical Trial; QALY, Quality Adjusted Life Year; ICER, Incremental Cost-Eﬀectiveness Ratio.
a Incremental cost per incremental QALY. All costs are in Euro.
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the treatment of chronic hepatitis BTo the Editor:
In their letter referring to our study “Modeling the
cost-eﬀectiveness of diﬀerent oral antiviral therapies inpatients with chronic hepatitis B”, Mantovani and de
Portu claim that the presentation of our results is inap-
propriate. We beg to disagree.
In our opinion, the only real contribution of the letter
by Mantovani and de Portu is when they point out that
lamivudine is a cost-eﬀective option in relation to “no
treatment”. This is a well-known fact that has little cur-
rent relevance, since lamivudine is not a recommended
ﬁrst-line option in the treatment of chronic hepatitis B
infection.
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1088 Letters to the Editor / Journal of Hepatology 51 (2009) 1082–1090First, the aim of our study, as is stated in the intro-
duction, was to assess the cost-eﬀectiveness of various
antiviral drugs [1]. The “no therapy” strategy was in-
cluded because a considerable number of patients with
chronic hepatitis B have their treatment deferred for dif-
ferent reasons. Secondly, as direct comparisons between
antiviral treatments are not available then indirect com-
parison remains the only approach to evaluate cost-
eﬀectiveness of any anti-HBV therapy. The limitations
of indirect treatment comparisons in cost assessment
are well recognized. For this reason, modeling tech-
niques are especially appropriate and indicated to com-
pare the data from diﬀerent sources [2]. Indeed,
modeling techniques allow extrapolation of short/med-
ium-term results from clinical trials to long-term eﬀec-
tiveness outcomes, which is what we did in our model,
in line with previous studies [3,4]. In addition, the prob-
abilistic sensitivity analysis helps the reader to better
understand eventual diﬀerences between the compared
options even if the primary data, virological response
rates, do not derive from head-to-head studies compar-
ing diﬀerent antiviral options, as occurs in chronic hep-
atitis B treatment. The robustness of our model was
exhaustively tested in the probabilistic analysis, and
the expected variability was analysed within the Monte
Carlo simulation. Finally, the basic cost-eﬀectiveness re-
sults depicted in Figures 1 and 2 of the manuscript [1]
clearly show that a number of treatment options are
dominated by others (in some cases by more than one
option) [1]. Thus, the only incremental cost-eﬀectiveness
ratios (ICERs) to be calculated are those of the more
eﬀective options relative to immediately less eﬀective op-
tions, performing a standard incremental cost-eﬀective-
ness analysis. In our study, ICERs are shown for
tenofovir vs. lamivudine and no treatment (Table 5 of
the manuscript [1]), and the only ICERs omitted are
those of lamivudine vs. no treatment in both HBeAg-po-
sitive and HBeAg-negative patients.Antiviral therapy for chronic hepatitis B: Challenges in Hong Kongq
To the Editor:
I read with great interest the review article by Prof.
Liaw published in a recent issue of this journal [1].
The article highlighted the reality and diﬃculties many
patients and clinicians in Asian countries are now facing
in the treatment of chronic hepatitis B. Although the
more recent antiviral agents (entecavir and tenofovir)
have strong antiviral potency and very low risk of drug
resistance, these drugs may not be available to all pa-
tients in need. This is due to the restricted reimburse-
ment criteria in place in diﬀerent countries as well as
the low income of the population in some areas.
In 2008, the gross national income per capita in Hong
Kong was approximately USD 30,380, which was com-
parable to that of Singapore, Japan, Australia and Eur-
ope [1]. Instead of full reimbursement for antiviral
drugs, Hong Kong has very restricted criteria of reim-
bursement. Before July 2008, lamivudine was the only
drug reimbursable to patients with signiﬁcant disease
activity while adefovir could only be reimbursed for pa-
tients with lamivudine resistance and signiﬁcant disease
activity. After July 2008, lamivudine was not reimburs-
able to treat new patients. Instead, entecavir could be
q HLYC is an advisory board member of Bristol-Myers Squibb,
Roche, Novartis Pharmaceutical, Pharmasset and Schering-Plough.
